Prostate cancer risk prediction using a polygenic risk score

[1]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[2]  B. Helfand,et al.  Germline Genetics of Prostate Cancer: Time to Incorporate Genetics into Early Detection Tools. , 2019, Clinical chemistry.

[3]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[4]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[5]  Thomas Agoritsas,et al.  Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis , 2018, British Medical Journal.

[6]  K. D. Sørensen,et al.  Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci , 2018, Nature Genetics.

[7]  H. Bang,et al.  Prostate-Specific Antigen–Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force , 2018, JAMA.

[8]  J. Sterne,et al.  Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial , 2018, JAMA.

[9]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[10]  G. Parmigiani,et al.  Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. , 2016, JAMA.

[11]  Martin Eklund,et al.  Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study. , 2015, The Lancet. Oncology.

[12]  J. Witte,et al.  Replication and Heritability of Prostate Cancer Risk Variants: Impact of Population-Specific Factors , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[13]  James L. Mohler,et al.  Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases , 2015, Human Genetics.

[14]  T. Tammela,et al.  Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up , 2014, The Lancet.

[15]  Michael J. Barry,et al.  Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. , 2014, JAMA.

[16]  K. Offit,et al.  Cancer genomics and inherited risk. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  P. Pharoah,et al.  Public health implications from COGS and potential for risk stratification and screening , 2013, Nature Genetics.

[18]  Peter Kraft,et al.  Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array , 2013, Nature Genetics.

[19]  Peter Kraft,et al.  Evaluation of polygenic risk scores for predicting breast and prostate cancer risk , 2011, Genetic epidemiology.

[20]  Martin Eklund,et al.  Polygenic risk score improves prostate cancer risk prediction: results from the Stockholm-1 cohort study. , 2011, European urology.

[21]  R. Hayes,et al.  Prostate Cancer Predisposition Loci and Risk of Metastatic Disease and Prostate Cancer Recurrence , 2011, Clinical Cancer Research.

[22]  P. Scardino,et al.  Susceptibility Loci Associated with Prostate Cancer Progression and Mortality , 2010, Clinical Cancer Research.

[23]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.

[24]  Yusuke Nakamura,et al.  Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel‐induced leukopenia , 2008, Cancer science.

[25]  W. Willett,et al.  Multiple loci identified in a genome-wide association study of prostate cancer , 2008, Nature Genetics.

[26]  A. Auvinen,et al.  The Finnish trial of prostate cancer screening: where are we now? , 2003, BJU international.

[27]  Douglas F. Easton,et al.  Polygenic susceptibility to breast cancer and implications for prevention , 2002, Nature Genetics.

[28]  S. Weinberg.  Where We Are Now , 1973, Science.

[29]  D. Brandeis,et al.  A Review of Current Evidence , 2014 .

[30]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.